BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Employees

728

Sector

Pharmaceuticals

Calendar

02-18 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
15/12/25	74.51 $	-0.85%	2,333,887
12/12/25	75.15 $	+1.46%	1,597,272
11/12/25	74.06 $	+1.88%	1,705,150
10/12/25	72.70 $	+1.44%	1,606,415
09/12/25	71.67 $	-3.46%	1,711,529

Delayed Quote Nasdaq, December 15, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

74.51USD

Average target price

85.78USD

Spread / Average Target

+15.12%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 15/12/2025 GMT			5-day change	1st Jan Change
74.51 ^USD	-0.85%		+0.36%	+171.54%

12-11	Bernstein Initiates BridgeBio Pharma at Outperform With $94 Price Target	MT
12-08	Bridgebio Pharma Insider Sold Shares Worth $5,908,476, According to a Recent SEC Filing	MT

Capitalization	14.36B 12.21B 11.42B 10.73B 19.77B 1,302B 21.6B 133B 51.48B 613B 53.88B 52.74B 2,229B	P/E ratio 2025 *	-21.6x	P/E ratio 2026 *	-43.4x
Enterprise value	15.54B 13.22B 12.37B 11.61B 21.4B 1,410B 23.38B 144B 55.73B 664B 58.32B 57.09B 2,413B	EV / Sales 2025 *	31.4x	EV / Sales 2026 *	17.3x
Free-Float	78.66%	Yield 2025 *	-	Yield 2026 *	-

12-11	Bernstein Initiates BridgeBio Pharma at Outperform With $94 Price Target	MT
12-08	Bridgebio Pharma Insider Sold Shares Worth $5,908,476, According to a Recent SEC Filing	MT
11-25	BridgeBio Pharma Insider Sold Shares Worth $1,722,224, According to a Recent SEC Filing	MT
11-20	Kyowa Kirin Co., Ltd. Initiates Phase 3 AOBA Study Of KK8398 (Infigratinib) In Patients With Achondroplasia In Japan	CI
11-19	Bridgebio Pharma Insider Sold Shares Worth $6,319,662, According to a Recent SEC Filing	MT
11-19	BridgeBio Pharma reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
11-19	BridgeBio Pharma Insider Sold Shares Worth $1,125,404, According to a Recent SEC Filing	MT
11-11	BridgeBio Pharma, Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 01:15 PM
11-10	Bridgebio Pharma Insider Sold Shares Worth $4,983,111, According to a Recent SEC Filing	MT
11-10	BridgeBio Pharma Insider Sold Shares Worth $3,888,999, According to a Recent SEC Filing	MT
11-08	BridgeBio Pharma, Inc. Presents Data from the ATTRibute-CM Study	CI
11-03	Mizuho Boosts Price Target on BridgeBio Pharma to $91 From $64, Keeps Outperform Rating	MT
10-31	Bridgebio Pharma Insider Sold Shares Worth $13,206,528, According to a Recent SEC Filing	MT

12-11	Bernstein Initiates BridgeBio Pharma at Outperform With $94 Price Target	MT
11-08	BridgeBio Pharma, Inc. Presents Data from the ATTRibute-CM Study	CI
11-03	Mizuho Boosts Price Target on BridgeBio Pharma to $91 From $64, Keeps Outperform Rating	MT
10-30	Analyst recommendations: Boeing, Alphabet, Caterpillar, Chipotle, Wayfair…
10-29	BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1	CI

BridgeBio Pharma, Inc. Share Price

Equities

BBIO

US10806X1028

Pharmaceuticals

Valuation: BridgeBio Pharma, Inc.

Chart: BridgeBio Pharma, Inc.

Latest news: BridgeBio Pharma, Inc.

Last Transcript: BridgeBio Pharma, Inc.

Analysts' recommendations: BridgeBio Pharma, Inc.

Press Releases: BridgeBio Pharma, Inc.

News in other languages: BridgeBio Pharma, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: BridgeBio Pharma, Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11-25	BridgeBio to Participate in December Investor Conferences	GL
11-19	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
11-10	BridgeBio Pharma : BBIO-Acoramidis AG10-AHA 2025- Vutisiran HCRU and discontinuation	PU
11-09	BridgeBio Pharma : BBIO-Acoramidis AG10-AHA 2025- D28 sTTR association with CVMCVH	PU
11-09	BridgeBio Pharma : BBIO-Acoramidis AG10-AHA 2025- Atrial fibrillation at baseline and clinical outcomes	PU

10-30	Wall Street : Toujours debout, mais légèrement chancelant
10-27	MÄRKTE USA/Fest - Börsianer setzen auf Entspannung zwischen USA und China
10-27	MÄRKTE USA/Fest - Neue KI-Chips beflügeln Qualcomm
10-27	MÄRKTE USA/Rekordlauf geht weiter - Technologieaktien favorisiert
09-29	Wall street parie (encore) contre le chaos

1 day	-0.85%
1 week	+0.36%
Current month	+3.47%
1 month	+12.23%
3 months	+44.76%
6 months	+87.31%
Current year	+171.54%

1 week	70.35	75.61
1 month	64.34	75.61
Current year	27.53	75.61
1 year	25.34	75.61
3 years	6.64	75.61
5 years	4.98	75.61
10 years	4.98	75.61

Manager	Title	Age	Since
Francis McCormick PRN	Corporate Officer/Principal	74	31/03/2019
Neil Kumar CEO	Chief Executive Officer	46	31/03/2015
Charles Homcy PRN	Corporate Officer/Principal	76	31/01/2019

Director	Title	Age	Since
Charles Homcy BRD	Director/Board Member	76	31/10/2018
Eric Aguiar BRD	Director/Board Member	63	28/02/2019
James Momtazee BRD	Director/Board Member	53	29/02/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BRIDGEBIO PHARMA, INC.	-0.85%	+0.36%	+171.04%	+736.25%	14.36B
REGENERON PHARMACEUTICALS, INC.	+1.53%	+7.02%	+2.92%	+2.92%	77.22B
CSL LIMITED	-1.20%	-2.57%	-36.00%	-39.27%	57.5B
SAMSUNG BIOLOGICS CO.,LTD.	+4.73%	+77.20%	+77.20%	+77.20%	55.88B
UCB	-0.29%	-1.94%	+28.03%	+224.81%	53.2B
BIOGEN INC.	+0.94%	-2.60%	+17.14%	-38.00%	25.78B
INNOVENT BIOLOGICS, INC.	-0.98%	-4.09%	+123.31%	+150.62%	18B
INCYTE CORPORATION	+3.39%	+2.01%	+43.89%	+19.96%	19.37B
ALTEOGEN INC.	+0.69%	-4.80%	+37.54%	+1,019.38%	15.88B
INTRA-CELLULAR THERAPIES, INC.	-0.04%	-.--%	+58.82%	+154.43%	14.02B
Average	+0.80%	-0.30%	+52.39%	+230.83%	35.12B
Weighted average by Cap.	+1.06%	+0.95%	+32.31%	+128.95%

	2025 *	2026 *
Net sales	496M 422M 394M 370M 683M 44.97B 746M 4.6B 1.78B 21.17B 1.86B 1.82B 76.97B	895M 761M 712M 669M 1.23B 81.16B 1.35B 8.3B 3.21B 38.2B 3.36B 3.29B 139B
Net income	-680M -578M -541M -508M -936M -61.64B -1.02B -6.3B -2.44B -29.02B -2.55B -2.5B -106B	-355M -302M -283M -266M -489M -32.24B -535M -3.3B -1.27B -15.17B -1.33B -1.31B -55.18B
Net Debt	1.18B 1.01B 942M 885M 1.63B 107B 1.78B 10.98B 4.25B 50.56B 4.44B 4.35B 184B	1.1B 933M 873M 820M 1.51B 99.49B 1.65B 10.17B 3.93B 46.83B 4.12B 4.03B 170B